Lukong KE[Author] - Search Results

Year	Number of Results
1998	1
1999	1
2000	2
2001	3
2003	1
2004	1
2005	1
2007	3
2008	4
2009	1
2012	1
2013	1
2014	4
2015	1
2016	3
2017	5
2018	5
2019	4
2020	3
2021	0

1

Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants.

Lukong KE, Ogunbolude Y, Kamdem JP. Lukong KE, et al. Breast Cancer Res Treat. 2017 Nov;166(2):351-365. doi: 10.1007/s10549-017-4408-0. Epub 2017 Aug 4. Breast Cancer Res Treat. 2017. PMID: 28776284 Review.

2

RNA-binding proteins in human genetic disease.

Lukong KE, Chang KW, Khandjian EW, Richard S. Lukong KE, et al. Trends Genet. 2008 Aug;24(8):416-25. doi: 10.1016/j.tig.2008.05.004. Epub 2008 Jul 1. Trends Genet. 2008. PMID: 18597886 Review.

3

Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects.

Nwabo Kamdje AH, Seke Etet PF, Simo Tagne R, Vecchio L, Lukong KE, Krampera M. Nwabo Kamdje AH, et al. Among authors: lukong ke. Front Cell Dev Biol. 2020 Nov 19;8:545126. doi: 10.3389/fcell.2020.545126. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33330442 Free PMC article. Review.

4

Bibliometric analysis of personalized humanized mouse and Drosophila models for effective combinational therapy in cancer patients.

Kamdem JP, Duarte AE, Ibrahim M, Lukong KE, Barros LM, Roeder T. Kamdem JP, et al. Among authors: lukong ke. Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165880. doi: 10.1016/j.bbadis.2020.165880. Epub 2020 Jun 24. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 32592936 Review.

5

Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects.

Kamdje AHN, Etet PFS, Simo RT, Vecchio L, Lukong KE, Krampera M. Kamdje AHN, et al. Among authors: lukong ke. Cancer Biol Med. 2020 Nov 15;17(4):828-841. doi: 10.20892/j.issn.2095-3941.2020.0133. Epub 2020 Dec 15. Cancer Biol Med. 2020. PMID: 33299638 Free PMC article. Review.

6

Understanding breast cancer - The long and winding road.

Lukong KE. Lukong KE. BBA Clin. 2017 Jan 27;7:64-77. doi: 10.1016/j.bbacli.2017.01.001. eCollection 2017 Jun. BBA Clin. 2017. PMID: 28194329 Free PMC article. Review.

7

Development of a low-cost and portable smart fluorometer for detecting breast cancer cells.

Alam MW, Wahid KA, Goel RK, Lukong KE. Alam MW, et al. Among authors: lukong ke. Biomed Opt Express. 2019 Jan 4;10(2):399-410. doi: 10.1364/BOE.10.000399. eCollection 2019 Feb 1. Biomed Opt Express. 2019. PMID: 30800488 Free PMC article.

8

Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.

Miah S, Bagu E, Goel R, Ogunbolude Y, Dai C, Ward A, Vizeacoumar FS, Davies G, Vizeacoumar FJ, Anderson D, Lukong KE. Miah S, et al. Among authors: lukong ke. BMC Cancer. 2019 Jan 16;19(1):78. doi: 10.1186/s12885-018-5186-8. BMC Cancer. 2019. PMID: 30651078 Free PMC article.

9

BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.

Miah S, Banks CAS, Ogunbolude Y, Bagu ET, Berg JM, Saraf A, Tettey TT, Hattem G, Dayebgadoh G, Kempf CG, Sardiu M, Napper S, Florens L, Lukong KE, Washburn MP. Miah S, et al. Among authors: lukong ke. Sci Adv. 2019 Oct 23;5(10):eaaw3113. doi: 10.1126/sciadv.aaw3113. eCollection 2019 Oct. Sci Adv. 2019. PMID: 31681835 Free PMC article.

10

Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates.

Goel RK, Meyer M, Paczkowska M, Reimand J, Vizeacoumar F, Vizeacoumar F, Lam TT, Lukong KE. Goel RK, et al. Among authors: lukong ke. Proteome Sci. 2018 Aug 18;16:16. doi: 10.1186/s12953-018-0143-7. eCollection 2018. Proteome Sci. 2018. PMID: 30140170 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results